Ivonescimab for Colorectal Cancer
Trial Summary
What is the purpose of this trial?
The goal of this clinical research study is to learn if ivonescimab can help to control previously treated, metastatic colorectal cancer.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that systemic anti-cancer treatment should not be taken within 14 days before starting the study treatment. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the drug Ivonescimab for colorectal cancer?
How is the drug Ivonescimab different from other treatments for colorectal cancer?
Ivonescimab is unique because it may target specific pathways involved in cancer growth, similar to other monoclonal antibodies like bevacizumab and cetuximab, which target blood vessel growth and epidermal growth factor receptors, respectively. This approach can potentially offer a new mechanism of action compared to traditional chemotherapy options.56789
Research Team
Saurav Haldar, MD
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
Adults over 18 with metastatic colorectal cancer that has worsened after treatment, including anti-PD-1/PD-L1 therapy. Participants must have measurable disease, a life expectancy over 3 months, and be able to provide recent tumor tissue. They should not have severe allergies or conditions that could affect study participation.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ivonescimab to evaluate its efficacy and safety in metastatic colorectal cancer
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Ivonescimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
Akesobio Australia Pty Ltd
Industry Sponsor
Summit Therapeutics Sub, Inc
Collaborator